Methotrexate + targeted therapy administration

ApprovedSmall molecule

UUniversity Hospital, Strasbourg, France

Methotrexate + targeted therapy administration is one of 32 small molecule programs targeting Rheumatoid Arthritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Rheumatoid ArthritisApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

118 2

Methotrexate + targeted therapy administration

UUniversity Hospital, Strasbourg, France

Approved

1 3

Simponi

Johnson & Johnson

Preclinical

19 4

Remicade

OOrganon and Co

Preclinical

43 5

Enbrel

IImmunex

Preclinical

64 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Celexa

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Post-ApprovalRecruiting

Rheumatoid Arthritis

NCT02714634

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT02714634·286 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methotrexate + targeted therapy administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methotrexate + targeted therapy administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methotrexate + targeted therapy administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Strasbourg, France

Methotrexate + targeted therapy administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News